70 East 55th Street, 14th Fl.
New York, NY email@example.com
Someone from our team will be in touch shortly.
Genomic Healthcare Leaders
Brogent harnesses the power of the human genome and other Real World Health Data to deliver precision medicine
Pioneers in Bioinformatics & Artificial Intelligence
Brogent’s Bioinformatic and AI experts specialize in advanced data analytics to determine personalized therapies and develop accelerated discovery pathways
Prevention & Population Health Experts
Brogent’s team has a proven track record of quantifiably improving morbidity and mortality measures for countries
Cancer Center & Hospital Consultation
Strategy, design, staffing, training, operations, regulatory and management solutions for NCI designated cancer centers and international standard clients
Global Health and Epidemiology
Expert solutions for governments, pharma, industry, and academic institutions with population-based and clinical data, molecular & genetic studies, and epidemiological analysis
Co-Founder, Executive Vice President for Scientific and Medical Affairs
70 East 55th Street, 14th Fl.
New York, NY firstname.lastname@example.org
Stephen Gruber is a Co-Founder of Brogent International LLC. Previously, Dr. Gruber served as Director of the USC Norris Comprehensive Cancer Center of the University of Southern California, one of the world’s leading cancer centers and one of only 11 dedicated cancer hospitals in the United States. At the University of Southern California, Dr. Gruber was the Jane & Kris Popovich Chair in Cancer Research at the University of Southern California and Professor of Medicine and Professor of Preventive Medicine, with tenure. Dr. Gruber was then appointed Vice President and Director of the Center for Precision Medicine at the City of Hope National Medical Center in Duarte, California. Dr. Stephen Gruber is a board-certified medical oncologist and internationally recognized physician-scientist with expertise in genomics, precision medicine, molecular epidemiology, and cancer genetics.
Under Dr. Stephen Gruber’s leadership, the USC Norris Comprehensive Cancer Center renewed its status as a NCI-designated Comprehensive Cancer Center in 2015, earned its highest distinction ever from the National Cancer Institute, and the USC Norris Cancer Hospital achieved its highest national ranking ever in US News and World Report in 2016. Prior to his role as Director of the USC Norris, Dr. Gruber held multiple leadership positions at the University of Michigan and University of Michigan Comprehensive Cancer Center, where he served on the faculty from 1997-2011. At the University of Michigan, Dr. Gruber held the H. Marvin Pollard Professor of Internal Medicine Endowed Chair, and was a tenured Professor of Internal Medicine, Professor of Epidemiology, and Professor of Human Genetics.
Dr. Stephen Gruber holds a B.A. in Biology and English from the University of Pennsylvania (1984), a M.P.H. (1986) and Ph.D. (1988) from Yale University, and M.D. from the University of Pennsylvania (1992). He completed his internship and residency in internal medicine at the University of Pennsylvania (1992-94), followed by a fellowship in medical oncology and a post-doctoral research fellowship at Johns Hopkins (1994-1997). Dr. Stephen Gruber is an elected member of the American Society of Clinical Investigation.
Dr. Peter Gruber is Professor of Surgery at the Yale University School of Medicine. Previously, he served as Chairman of the Departed of Cardiothoracic Surgery and Co-director of the Abboud Cardiovascular Research Center at the Carver College of Medicine. Over the past two decades, his research and clinical practice have focused on complex congenital heart disease; its molecular and genetic underpinnings, and therapies to improve cardiac function. He has contributed to discoveries that have shown the importance of epigenetic factors, especially histone deacetylases, in cardiac development and its response to ischemia reperfusion injury. His surgical practice in repair of complex congenital heart disease augments the science by focusing upon clinically relevant problems. In his role as Co-director of the Abboud Cardiovascular Research Center, he created a collaborative, cross-disciplinary environment for scientists in cardiovascular biology. He earned his B.A. in Biochemistry from the University of Pennsylvania (1985), M.D. from the University of Pennsylvania School of Medicine (1992), and Ph.D. from the University of Pennsylvania, in Biochemistry and Biophysics (1992). He completed his dissertation in the Laboratory of Biochemical Genetics and Metabolism at Rockefeller University. His post-doctoral fellowship in Cardiac Development was completed at the American Heart Association Bugher Foundation Center for Molecular Biology at the University of California, San Diego (1994-1996). His clinical training in General and Cardiothoracic Surgery was completed at the Johns Hopkins Hospital (1992-1999) and Pediatric Cardiothoracic Surgery at The Children’s Hospital of Philadelphia (2002). He has held faculty appointments as Assistant Professor of Surgery at the University of Pennsylvania School of Medicine (2002-2011), the D. Rees and Eleanor T. Jensen Presidential Chair at the University of Utah School of Medicine (2011-2014), Professor and Chair of Surgery at the University of Iowa (2014-2016), and Professor of Surgery at the Yale School of Medicine (2018-present). He is an elected member of the American Society of Clinical Investigation and the American Surgical Association. He has published over 150 scientific publications.
Paul Scibetta is the Co-Founder, Chairman, and CEO of Brogent International LLC. Mr. Scibetta is the CEO of PacificBridge Capital LLC, a leading investment firm providing capital and value add capabilities for unique early stage ventures with the ability to change the world.
Mr. Scibetta previously held leadership positions with JPMorgan for 15 years in a career that included two postings in Asia, as well as postings in Europe and the United States. During the majority of his career with JPMorgan, he served as CEO of JPMorgan portfolio companies. Mr. Scibetta served as CEO and Managing Director of The JPMorgan Private Bank in Asia (2007-2011), based in Hong Kong. During this time, Mr. Scibetta was a member of the Private Bank's Global Operating Committee and Global Risk Committee, and JPMorgan's Asia Executive Committee. Prior to this period, Mr. Scibetta served as a member of the JPMorgan Asset Management Global Operating Committee (2002-2006), and as a CEO of businesses within JPMorgan Asset Management, based in New York. Prior to Mr. Scibetta's chief executive roles, he served in leadership positions for JPMorgan Asset Management as an attorney, risk officer and Global Chief Fiduciary Officer from 1997-2003. Mr. Scibetta joined JPMorgan in 1997 in Tokyo where he served as Head of Legal and Compliance for JPMorgan's Asia Investment Management and Private Banking (IMPB) business (1997-1999). He relocated in 1999 to London, where he held the position Head of Legal and Compliance for JPMorgan's Europe IMPB business (1999-2001).
Prior to joining JPMorgan, Mr. Scibetta served as an Associate at Cleary Gottlieb Steen & Hamilton in New York (1992-1995) and Tokyo (1995-1997), and clerked for the Honorable Conrad K. Cyr of the United States Court of Appeals for the First Circuit (1991-1992). Mr. Scibetta holds a B.S. in Economics from James Madison University and a J.D. from the University of Pittsburgh School of Law.
Following his distinguished career at the City of Hope National Medical Center in the United States, Dr. Yun Yen was appointed President of Taipei Medical University, leading the university and three hospitals to international distinction. By recruiting international faculty from Harvard and other distinguished universities across the globe, Dr. Yun Yen raised the profile and world ranking of his institution. Dr. Yen increased the global visibility and branding of TMU with international scholarships and visiting faculty, and gained further recognition for executive leadership of health enterprises across Asia. Dr. Yun Yen is a native speaker in both Mandarin and English.
As executive leader and President of three hospitals in the Taipei Medical University Health System, Dr. Yun Yen was responsible for clinical operations, administration, quality standards, physician staffing, education, patient safety, and hospital finances. A key international metric for high-quality medical care is accreditation by the Joint Commission International, which is the international branch of the Joint Commission on Accreditation of Healthcare Organizations. Dr. Yun Yen was the first to achieve accreditation for all three hospitals from the Joint Commission International.
Under the leadership of Dr. Yun Yen, the collaboration between Taipei Medical University and Ningbo Government established a pioneering model of hospital entrusted management. With importing advanced hospital management concepts from Taipei Medical University Healthcare Systems, Li Huili Eastern Hospital began operations in December 2015, and provides 1,000 beds with comprehensive healthcare service. It is a new medical collaboration model in China: the hospital is established by the government and operated by the private sector. The hospital specializes in cancer treatment, organ transplantation, urinary kidney disease, gynecologic surgery and pediatrics, health examinations and international medical care. The hospital focuses on medical education and research, and it seeks to practice the "medical ethics" and "humanity and art" within its whole system while integrating Taiwan’s high standards for medical service.
Dr. Rennert is Director of the National Israeli Cancer Control Center and is Professor and Chair of the Department of Preventive Medicine at the Technion University in Israel. Dr. Rennert initiated and organized the National Israeli Breast Cancer Screening Program that was responsible for all elements of screening of an entire population, including the organization of 100 mammography centers, inviting women in appropriate age ranges, and centralizing computing systems for all mammography centers. This full program included mammography, risk factor identification and management, radiology, surgery, pathology, and oncology. Every encounter with the system was registered and computerized, with over 10 million encounters of over 3 million women. This program evaluated the quality of every center for detection rate, false negative rate, false positive rate, surgical quality, and pathology quality, all performed in a positive feedback loop to help centers improve their performance. This program included “hot pursuit” of women who had positive screening to ensure appropriate clinical follow-up. The program demonstrated measurable reduction in breast cancer mortality by 10-15% for the entire country of Israel. The program has been in place for more than 20 years. Dr. Rennert also led a team that investigated the international radiation exposure and health outcomes of populations exposed to radiation from Chernobyl in south Belarus and north Ukraine, under the oversight of a joint commission of Russia and the United States. Dr. Rennert organized all surveillance and follow-up of all immigrants to Israel from the exposed region and surveillance of the radiation site liquidators. Approximately 350,000 immigrants and 1,500 liquidators who were within 30km of the nuclear site were seen for health exams, health maintenance and follow-ups.
Dr. Rennert organized a comprehensive screening program for colorectal cancer for the entire country of Israel, mailing self-administered kits to homes, which were returned to clinics, and processed in a central laboratory. In 2017, the central laboratory under Dr. Rennert’s oversight performed 2,500 screening tests per day. Quality assurance is developed throughout the entire program, and every positive test result is followed with hot pursuit. The entire computerized system provides for full annotation of all data elements of the screening program and clinical follow-up. With the introduction of this program, 70% of detected cases in Israel are now early stage colon cancer, and the program has led to at least a 10% reduction in mortality from colon cancer across the country.
Brian Athey, Ph.D. is the Michael Savageau Collegiate Professor and Founding Chair of the Department of Computational Medicine and Bioinformatics in the University of Michigan Medical School, where he also has appointments as a Professor of Psychiatry and of Internal Medicine. He has previously served as Director of Academic and Clinical Informatics for the School. Brian also serves as Founding Co-director of the U-M wide Michigan Institute for Data Science (MIDAS). Brian is the Principal Investigator of one of the most well-established NIH Pre-Doctoral Training Programs in Bioinformatics in the US. He has served as the Principal Investigator on many seminal efforts such as the NIH Visible Human Project, DARPA Virtual Soldier Project and the NIH National Center for Integrative Biomedical Informatics. He was Co-founder and later CSO of the tranSMART Foundation, a data integration and analytics platform utilized by the pharmaceutical industry globally. Brian’s recent research is the creation and use of bioinformatics pipelines, epigenomics, Electronic Health Records (EHRs), and machine learning methods to radically improve the efficacy of Pharmacogenomics, and is considered a pioneer researcher in the new field of “Pharmacoepigenomics”. From 2010-2016, he served as Chair of Scientific Advisory Board (SAB) of Assurex Health, Inc. (Mason, OH), the leading psychiatric pharmacogenomics company in the world, recently acquired by Myriad Genetics, Inc. (Salt Lake City, UT). He has consulted extensively for the Defense Advanced Research Projects Agency (DARPA), the NIH Office of the Director, the NIH Chief Information Officer. Since 2017, Brian has served as an advisor to the Chinese University Hong Kong, Shenzhen (CUHK-SZ). He is an elected Fellow of the American College of Medical Informatics (FACMI).